Cutaneous side effects of antiangiogenic agents;Effets secondaires cutanés des molécules anti- angiogéniques

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antiangiogenic agent; Side effect; Skin pathophysiology

Indexed keywords

BEVACIZUMAB; IMATINIB; SORAFENIB; SUNITINIB; VASCULOTROPIN;

CANCER THERAPY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; PATHOPHYSIOLOGY; REVIEW; SKIN DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; DRUG ERUPTIONS; HUMANS; INDOLES; PIGMENTATION DISORDERS; PYRIDINES; PYRROLES; SKIN DISEASES;

EID: 34548616412     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0417     Document Type: Review

References (19)

1. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005 ; 6 : 491-500.
2. Bikfalvi A. [Tumor angiogenesis]. Bull Cancer 2003 ; 90 : 449-58.
3. Gotlib V, Khaled S, Lapko I, et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006 ; 17 : 1227-9.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 ; 356 : 125-34.
5. Young JB, Will EJ, Mulley GP. Splinter haemorrhages : facts and fiction. JR Coll Physicians Lond 1988 ; 22 : 240-3.
6. Mujic F, Lloyd M, Cuadrado MJ, et al. Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1995 ; 13 : 327-31.
7. Monk BE. The prevalence of splinter haemorrhages. Br J Dermatol 1980 ; 103 : 183-5.
8. Robert C, Faivre S, Raymond E, et al. Subungual splinter hemorrhages : a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005 ; 143 : 313-4.
9. Janusch M, Fischer M, Marsch W, et al. The hand-foor syndrome : a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006 ; 16 : 494-9.
10. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006 ; 31 : 783-5.
11. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007 ; 56 : 171-2.
12. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006 ; 368 : 1303-4.
13. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 ; 356 : 115-24.
14. Robert C, Spatz A, Faivre S, et al. Tyrosine kinase inhibition and grey hair. Lancet 2003 ; 361 : 1056.
15. Moss KG, Toner GC, Cherrington JM, et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003 ; 307 : 476-80.
16. Wu M, Hemesath TJ, Takemoto CM, et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 2000 ; 14 : 301-12.
17. Papin C, Barnier JV, Eychene A, et al. [B-raf gene encodes for multiple isoforms with Mek-1 kinase activity]. C R Seances Soc Biol Fil 1995 ; 189 : 71-85.
18. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents : is there a silver lining? J Clin Oncol 2005 ; 23 : 5235-46.
19. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours : Is rash associated with treatment outcome? Eur J Cancer 2006 ; 42 : 548-56.